UNSPSC 51281635: Arbekacin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C22H44N6O10.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7395HZ992, chemically known as d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-n-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)-, sulfate (salt) but more generally known as arbekacin sulfate, which bears US NIH Compound Identifier 175989.

UNSPSC 51281635 Arbekacin sulfate is a Commodity code that nominally identifies a single antibiotic pharmaceutical product, but the recent state and local opportunities tagged under it show little activity directly aligned with that narrow scope. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets—antibiotics in a different family than arbekacin. Seminole County, Florida posted an IFB for naloxone and safe drug deactivation systems, a public-health procurement unrelated to the code's stated product. The issuing bodies include a state health department and a county government, reflecting fragmented procurement authority across public health jurisdictions, but the mismatch between the code label and the actual goods being solicited suggests either miscoding of opportunities or minimal recent demand for arbekacin specifically under this taxonomy entry.

Geographic activity appears concentrated in Florida and Illinois based on the recent postings, though the sample is too small to characterize broader regional concentration. The Illinois award (Bid Number 26482DPHPREPDB53392, completed August 28, 2026, $2.999999 million over three years including renewals) was an IFB awarded to a single vendor after a lowest-price evaluation; Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) sought annual quantities of 1,900 units of naloxone and 800 deactivation systems with quarterly deliveries and a two-year initial term. Neither opportunity represents current demand for arbekacin sulfate as specified by the code. Firms evaluating this code should verify whether state and local procurement offices are currently tagging arbekacin acquisitions under this entry or whether the recent postings reflect systematic miscoding rather than active market demand.